- cafead   Jun 12, 2023 at 10:02: AM
via Friday, Editas Medicine unveiled early data from the RUBY and EdiTHAL trials, demonstrating the potential of its gene editor EDIT-301 in sickle cell disease and transfusion-dependent beta thalassemia.
article source
article source